Skip to content
Home » UKVIA publishes its 2025 annual report

UKVIA publishes its 2025 annual report

The UK Vaping Industry Association has published its 2025 Annual Report, setting out what has been one of the most consequential years to date for the UK vaping sector.

Against a backdrop of significant regulatory change, political transition and heightened scrutiny, the report documents how the UKVIA has continued to champion evidence-based policy, robust enforcement and the vital role vaping plays in reducing smoking rates across the UK.

Official data shows smoking prevalence has fallen to record lows, yet around five million people still smoke, underlining the importance of ensuring adult smokers retain access to regulated, reduced-risk alternatives.

The report details the Association’s extensive engagement with policymakers throughout the year, including sustained work on the Tobacco and Vapes Bill, the introduction of the single-use vapes ban and preparations for the forthcoming Vaping Products Duty. The UKVIA consistently argues for proportionate regulation that protects young people while avoiding unintended consequences that risk driving adults back to smoking or into the illicit market.

A major focus during 2025 was tackling illegal and underage sales. The UKVIA’s Be Vape Vigilant campaign reached a significant milestone, with around 1,500 reports of suspected illegal or underage vape sales submitted since launch. The Association also played a central role in developing a proposed national vape retail and distributor licensing framework, designed to strengthen enforcement, raise standards across the supply chain and ensure responsible businesses are not undercut by rogue operators.

Public education remained a cornerstone of UKVIA activity. VApril returned for an eighth year, delivering the world’s largest vaping awareness campaign at a time when misperceptions about vaping are at record levels. The campaign generated more than 690,000 impressions and over 32,000 website visits, reinforcing the evidence on vaping and supporting smokers to make informed choices. Alongside this, new research highlighted gaps in smoking cessation training across the NHS, prompting the launch of the UKVIA Healthcare Hub to better equip health professionals with evidence-based guidance.

The Annual Report also reflects the Association’s international engagement, high-profile media presence and the collective contribution of its committees and members. Looking ahead to 2026, the report outlines upcoming initiatives including VapeVerify and VapeWatch, aimed at challenging bad science and misleading reporting, as well as work on a new Vape Notification Framework to strengthen compliance from submission to sale.

As the sector enters another pivotal year, the 2025 Annual Report reinforces the UKVIA’s commitment to supporting responsible regulation, effective enforcement and policies that help deliver a smoke-free future without undermining harm reduction for adults.

Ends

53 thoughts on “UKVIA publishes its 2025 annual report”

  1. Pingback: metoprolol succinate

  2. Pingback: lasix diuretic

  3. Pingback: fluconazole 150 mg

  4. Pingback: viagra prix

  5. Pingback: uti antibiotics online

  6. Pingback: meloxicam 7.5 mg cost without insurance

  7. Pingback: azitromicina

  8. Pingback: doxycycline for dogs

  9. Pingback: antibiotics for tooth infection

  10. Pingback: sertraline hydrochloride 50mg tablet

  11. Pingback: misoprostol 200mcg price

  12. Pingback: rifampicina

  13. Pingback: diflucan over the counter uk

  14. Pingback: zydena tablet

  15. Pingback: fluconazole tablet 150 mg

  16. Pingback: doxycycline hyclate 100mg price

  17. Pingback: avidoxy

  18. Pingback: invictus tadalafil review

  19. Pingback: xenical reviews australia

  20. Pingback: what is vidalista

  21. Pingback: tadalafil generico 5mg

  22. Pingback: what is cenforce 150

  23. Pingback: cenforce d tablet review

  24. Pingback: vidalista tadalafil 20mg

  25. Pingback: xenical pilule

  26. Pingback: dutasteride spray

  27. Pingback: finasteride prescription cost

  28. Pingback: sémaglutide injection prix état de new york

  29. Pingback: finasteride propecia

  30. Pingback: proscar for hair growth

  31. Pingback: doxycycline for back acne

  32. Pingback: metronidazole gel 0.75 1x50g

  33. Pingback: alternative to metronidazole gel

  34. Pingback: minoxidil tablets reviews

  35. Pingback: acyclovir suspension

  36. Pingback: saxenda pen image

  37. Pingback: toradol for back pain

  38. Pingback: ivermectin demodex medical summary

  39. Pingback: ivermectin rosacea expert insights

  40. Pingback: minoxidil clinical proof

  41. Pingback: minoxidil for male pattern hair loss

  42. Pingback: minoxidil women’s timeline

  43. Pingback: sildenafil signal transduction

  44. Pingback: sildenafil online safety

  45. Pingback: sildenafil packaging cost factors

  46. Pingback: vardenafil caution considerations

  47. Pingback: Absorption Rate Reference

  48. Pingback: Pharmacology of Onset Variability

  49. Pingback: understanding sildenafil vs tadalafil

  50. Pingback: Sildenafil vs vardenafil mechanism

  51. Pingback: Viagra vs sildenafil effectiveness

  52. Pingback: Sildenafil vs Cialis Duration Differences

  53. Pingback: sildenafil brands and formulations

Leave a Reply

It’s time for a Fair Deal for Vaping

Vaping has helped millions of adults quit smoking, but excessive regulation risks making it harder to switch to a less harmful alternative.

Responsible businesses are being lumped in with the rogue players we all want driven out.

We need tougher action on rogue traders, not policies that make legal vaping more expensive and less accessible.

It’s time for a Fair Deal for Vaping.